Despite the lack of effective treatments for most retinal dystrophies, recent advances in gene therapy, particularly the approval of Luxturna for RPE65-associated retinal dystrophies, offer new hope for therapeutic intervention, with several ongoing clinical trials targeting other subtypes [4]. This evidence concerns the gene RPE65 and inherited retinal dystrophy.